Well I can't say I'm disappointed with that announcement and I can understand Marg's comment about Carter being "excited" about Anagrelide.
The technical description was undoubtedly written by one of the good professors on the SAB and Carter threw in his two bob's worth in how SUD fits in. Quite a good read I reckon.
With regard to timelines there's no point. This is a decade away from your quack referring you to an oncologist and he giving you a scrip for the Anagrelide oral spray.
Best case scenario is that SUD's chemists get the formulation stable and demonstrate that it works in vitro. Then big pharma comes in an takes over with upfronts, milestones and royalties. SUD trying to do human proof of concept trials will be costly and that's not their core business. I agree with this being one of the products of focus.
With regards to funding, the non-dilutionary tax effective investment for the subsidiary is a good, without having seen the terms and conditions.
There is some good stuff happening but no cashflow which means my buy at 0.4 c will probably get hit. A trade sale of artimist for 15 million and 5 of which is returned to shareholders as a special divvy would offer some SP support I would think. Also in the next couple of quarters if migraine formulation starts to pay its own way, one would think that that would also be supportive.
I agree with all posters who are concerned that the SP is sh!t, I've been in this dog for a decade now and I'll have to wait another decade to be able buy anagrelide but in the mean time...…….?
SUD Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
